Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

Phase 1 Recruiting 76 enrolled Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.

Timeline

Start: 2025-03-21
Primary completion: 2025-08-30
Completion: 2025-10-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HL-1186	Unknown	—	Oral

Indications

No indication recorded.